EP1315512A4 - Ciblage ad noviral et manipulation de la r ponse du syst me immunitaire au moyen de peptides ciblants - Google Patents
Ciblage ad noviral et manipulation de la r ponse du syst me immunitaire au moyen de peptides ciblantsInfo
- Publication number
- EP1315512A4 EP1315512A4 EP01970682A EP01970682A EP1315512A4 EP 1315512 A4 EP1315512 A4 EP 1315512A4 EP 01970682 A EP01970682 A EP 01970682A EP 01970682 A EP01970682 A EP 01970682A EP 1315512 A4 EP1315512 A4 EP 1315512A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- disclosed
- targeting
- peptides
- novel
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23126600P | 2000-09-08 | 2000-09-08 | |
US231266P | 2000-09-08 | ||
US76510101A | 2001-01-17 | 2001-01-17 | |
US765101 | 2001-01-17 | ||
PCT/US2001/028045 WO2002020724A2 (fr) | 2000-09-08 | 2001-09-07 | Ciblage adénoviral et manipulation de la réponse du système immunitaire au moyen de peptides ciblants |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1315512A2 EP1315512A2 (fr) | 2003-06-04 |
EP1315512A4 true EP1315512A4 (fr) | 2005-11-09 |
Family
ID=26924954
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01970671A Withdrawn EP1315965A4 (fr) | 2000-09-08 | 2001-09-07 | Procedes et compositions utilises pour le ciblage in vitro |
EP01968683A Withdrawn EP1315840A4 (fr) | 2000-09-08 | 2001-09-07 | Biopanning et analyse rapide de ligands interactifs selectifs (brasil) |
EP01970682A Withdrawn EP1315512A4 (fr) | 2000-09-08 | 2001-09-07 | Ciblage ad noviral et manipulation de la r ponse du syst me immunitaire au moyen de peptides ciblants |
EP08016646A Withdrawn EP2028187A1 (fr) | 2000-09-08 | 2001-09-07 | Peptides cibles chez l'homme et la souris identifiées par l'affichage de phases |
EP01968603A Expired - Lifetime EP1322755B1 (fr) | 2000-09-08 | 2001-09-07 | Peptides de ciblage humains et murins identifies par expression phagique |
EP01970681A Withdrawn EP1315830A4 (fr) | 2000-09-08 | 2001-09-07 | Compositions et procedes se rapporant a des peptides ciblants chez l'homme in vivo |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01970671A Withdrawn EP1315965A4 (fr) | 2000-09-08 | 2001-09-07 | Procedes et compositions utilises pour le ciblage in vitro |
EP01968683A Withdrawn EP1315840A4 (fr) | 2000-09-08 | 2001-09-07 | Biopanning et analyse rapide de ligands interactifs selectifs (brasil) |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08016646A Withdrawn EP2028187A1 (fr) | 2000-09-08 | 2001-09-07 | Peptides cibles chez l'homme et la souris identifiées par l'affichage de phases |
EP01968603A Expired - Lifetime EP1322755B1 (fr) | 2000-09-08 | 2001-09-07 | Peptides de ciblage humains et murins identifies par expression phagique |
EP01970681A Withdrawn EP1315830A4 (fr) | 2000-09-08 | 2001-09-07 | Compositions et procedes se rapporant a des peptides ciblants chez l'homme in vivo |
Country Status (7)
Country | Link |
---|---|
EP (6) | EP1315965A4 (fr) |
JP (6) | JP2004515751A (fr) |
AT (1) | ATE478141T1 (fr) |
CA (5) | CA2421195A1 (fr) |
DE (1) | DE60142840D1 (fr) |
PT (1) | PT1322755E (fr) |
WO (4) | WO2002020723A2 (fr) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU762991B2 (en) * | 1998-03-13 | 2003-07-10 | Burnham Institute, The | Molecules that home to various selected organs or tissues |
US7452964B2 (en) | 2001-09-07 | 2008-11-18 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
AU2001290663A1 (en) * | 2000-09-08 | 2002-03-22 | Board Of Regents, The University Of Texas System | Adenoviral targeting and manipulation of immune system response using targeting peptides |
US7420030B2 (en) | 2000-09-08 | 2008-09-02 | The Board Of Regents Of The University Of Texas System | Aminopeptidase A (APA) targeting peptides for the treatment of cancer |
US20040170955A1 (en) | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
US7671010B2 (en) | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
US8507445B2 (en) | 2001-09-07 | 2013-08-13 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
US7371719B2 (en) | 2002-02-15 | 2008-05-13 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
EP1346729A1 (fr) * | 2002-03-19 | 2003-09-24 | Cardiovascular Research Institute Maastricht | Cibler l'angiogénèse du myocarde à l'aide de CD13/APN |
US9321992B2 (en) | 2002-06-14 | 2016-04-26 | Case Western Reserve University | Cell targeting methods and compositions |
EP1546714A4 (fr) * | 2002-08-30 | 2007-12-05 | Univ Texas | Compositions et procedes d'utilisation de peptides de ciblage con us pour le diagnostic et le traitement du cancer humain |
US7554021B2 (en) | 2002-11-12 | 2009-06-30 | Northwestern University | Composition and method for self-assembly and mineralization of peptide amphiphiles |
WO2004084950A2 (fr) * | 2003-03-24 | 2004-10-07 | Case Western Reserve University | Procedes et compositions de ciblage cellulaire |
CA2523197C (fr) * | 2003-04-22 | 2016-05-24 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Vectors de peptide |
US20040248109A1 (en) * | 2003-06-09 | 2004-12-09 | Lawrence Greenfield | Methods for selecting protein binding moieties |
US20050187161A1 (en) * | 2003-09-12 | 2005-08-25 | Board Of Regents, The University Of Texas System | Biopanning as an approach to study the pathogenesis of and produce novel treatment modalities for invasive Aspergillosis |
JP2011239784A (ja) * | 2003-12-04 | 2011-12-01 | Perseus Proteomics Inc | 細胞表面抗原に対する抗体取得とその抗原同定 |
JP4870348B2 (ja) * | 2003-12-04 | 2012-02-08 | 株式会社ペルセウスプロテオミクス | 細胞表面抗原に対する抗体取得とその抗原同定 |
CA2549164A1 (fr) * | 2003-12-05 | 2005-06-23 | Northwestern University | Amphiphiles peptidiques a assemblage automatique et procedes associes d'administration de facteur de croissance |
US8377484B1 (en) * | 2004-05-06 | 2013-02-19 | Maria V. Tsiper | Tumor encapsulation for prevention and treatment of metastatic cancer disease |
CN1294418C (zh) * | 2004-08-09 | 2007-01-10 | 中国人民解放军南京军区南京总医院 | 检测白念珠菌菌丝蛋白抗体的方法及试剂盒 |
GB0422431D0 (en) * | 2004-10-08 | 2004-11-10 | Affitech As | Method |
ITRM20040568A1 (it) * | 2004-11-18 | 2005-02-18 | Uni Degli Studi Di Roma Tor Vergata | Uso della tecnica "phage display" per l'identificazione di peptidi con capacita' di legame a cellule staminali/progenitore, peptidi cosi' ottenuti e loro usi. |
JP2008539209A (ja) * | 2005-04-26 | 2008-11-13 | カリヨン−シーティーティー リミテッド | 診断及び治療剤 |
CA2822302A1 (fr) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Procedes pour alterer la differenciation osteoclaste |
US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
AU2007222991A1 (en) * | 2006-03-09 | 2007-09-13 | The Board Of Regents Of The University Of Texas System | Compositions and methods based on peptide binding profiling |
CA2679266A1 (fr) * | 2007-02-27 | 2008-09-04 | Forerunner Pharma Research Co., Ltd. | Composition pharmaceutique comportant un anticorps anti-grp 78 en tant qu'ingredient actif |
US8076295B2 (en) | 2007-04-17 | 2011-12-13 | Nanotope, Inc. | Peptide amphiphiles having improved solubility and methods of using same |
US7807630B2 (en) * | 2007-09-14 | 2010-10-05 | Vanderbilt University | Targeting of Notch3 receptor function for cancer therapy |
CN106995495A (zh) * | 2009-01-12 | 2017-08-01 | 希托马克斯医疗有限责任公司 | 修饰抗体组合物及其制备和使用方法 |
WO2010120830A1 (fr) | 2009-04-13 | 2010-10-21 | Northwestern University | Nouvelles structures peptidiques pour la régénération des cartilages et procédés pour les utiliser |
DK2683393T3 (en) | 2011-02-11 | 2018-07-23 | Univ Michigan Regents | TRIPEPTIME COMPOSITIONS AND THEIR USE IN TREATING DIABETES |
US20150105274A1 (en) * | 2012-02-10 | 2015-04-16 | Phylogica Limited | Methods for the Characterisation of Interaction Sites on Target Proteins |
WO2013149237A1 (fr) * | 2012-03-30 | 2013-10-03 | Board Of Regents, The University Of Texas System | Ciblage intracellulaire de signaux de localisation spécifique pour des organites avec des ligands fonctionnels autoguidés dérivés de bibliothèques combinatoires de phages d'internalisation dans des cellules |
MX2015000863A (es) | 2012-07-19 | 2016-05-05 | Alethia Biotherapeutics Inc | Anticuerpos anti-siglec-15. |
GB201308745D0 (en) * | 2013-05-15 | 2013-06-26 | Imp Innovations | Bacteriophage |
CN103497236B (zh) * | 2013-09-25 | 2017-05-10 | 浙江省医学科学院 | 靶向wisp‑1蛋白的特异性七肽及其应用 |
GB2522412A (en) * | 2014-01-22 | 2015-07-29 | Agency Science Tech & Res | Antimicrobial peptidomimetics |
BR112016016274A2 (pt) | 2014-02-19 | 2017-10-03 | Hoffmann La Roche | Ponte da barreira hematoencefálica |
WO2015177098A2 (fr) * | 2014-05-19 | 2015-11-26 | Helsingin Yliopisto | Adénovirus modifiés pour le développement de vaccins contre le cancer |
CN105769909A (zh) * | 2016-05-13 | 2016-07-20 | 云南舜喜再生医学工程有限公司 | 一种直接获得富含细胞因子血清的采血器及方法 |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
KR101921836B1 (ko) | 2017-11-23 | 2018-11-26 | 서울대학교병원 | 피부성체 줄기세포의 분화 조절 방법, 및 피부성체 줄기세포의 분화 조절용 조성물 및 키트 |
EP3856224A4 (fr) * | 2018-09-25 | 2022-07-06 | Emory University | Acides nucléiques pour la reconnaissance et l'intégration de cellules |
CN109137086A (zh) * | 2018-10-16 | 2019-01-04 | 梁耀极 | 一种改良的全长mRNA测序的建库方法 |
BR102019014302A2 (pt) | 2019-07-10 | 2021-12-28 | Universidade Federal de Uberlândia | Peptídeos recombinantes ligantes ao anticorpo tumoral específico para cancer de mama e uso |
EP3767628B1 (fr) | 2019-07-18 | 2024-03-27 | Bayer Aktiengesellschaft | Sélection d'anticorps / de fragments d'anticorps |
MX2022007465A (es) * | 2019-12-17 | 2022-08-15 | Univ Mie | Metodos y composiciones para evaluar y tratar fibrosis. |
GB202211043D0 (en) * | 2022-07-28 | 2022-09-14 | Univ Birmingham | Peptide agonist |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999046284A2 (fr) * | 1998-03-13 | 1999-09-16 | The Burnham Institute | Molecules se logeant dans divers organes ou tissus |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US5206347A (en) | 1985-08-06 | 1993-04-27 | La Jolla Cancer Research Foundation | Isolation and use of receptors binding to a peptide column |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5252296A (en) | 1990-05-15 | 1993-10-12 | Chiron Corporation | Method and apparatus for biopolymer synthesis |
CA2079444C (fr) | 1991-02-14 | 2004-02-03 | Rimona Margalit | Liaison de substances de reconnaissance a des liposomes |
US5603872A (en) | 1991-02-14 | 1997-02-18 | Baxter International Inc. | Method of binding recognizing substances to liposomes |
US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
EP0700522A1 (fr) * | 1993-05-28 | 1996-03-13 | Chiron Corporation | Procede de selection de sequences de peptides biologiquement actifs |
US5492807A (en) | 1993-11-19 | 1996-02-20 | Santi; Daniel V. | Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease |
US5622699A (en) | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
EP0987275B1 (fr) * | 1995-09-11 | 2008-01-02 | La Jolla Cancer Research Foundation | Molécules qui s'adressent in vivo vers un organe ou tissu prélevé |
US6068829A (en) | 1995-09-11 | 2000-05-30 | The Burnham Institute | Method of identifying molecules that home to a selected organ in vivo |
WO2000014215A1 (fr) * | 1998-09-07 | 2000-03-16 | Eberhard-Karls-Universität Tübingen | Procede de selection de peptides pour le transport cible de medicaments et de marqueurs et peptides decouverts a l'aide dudit procede |
-
2001
- 2001-09-07 JP JP2002525729A patent/JP2004515751A/ja not_active Withdrawn
- 2001-09-07 EP EP01970671A patent/EP1315965A4/fr not_active Withdrawn
- 2001-09-07 WO PCT/US2001/028044 patent/WO2002020723A2/fr not_active Application Discontinuation
- 2001-09-07 WO PCT/US2001/027702 patent/WO2002020722A2/fr not_active Application Discontinuation
- 2001-09-07 CA CA002421195A patent/CA2421195A1/fr not_active Abandoned
- 2001-09-07 EP EP01968683A patent/EP1315840A4/fr not_active Withdrawn
- 2001-09-07 JP JP2002525828A patent/JP2004530404A/ja not_active Withdrawn
- 2001-09-07 DE DE60142840T patent/DE60142840D1/de not_active Expired - Lifetime
- 2001-09-07 EP EP01970682A patent/EP1315512A4/fr not_active Withdrawn
- 2001-09-07 EP EP08016646A patent/EP2028187A1/fr not_active Withdrawn
- 2001-09-07 CA CA002421380A patent/CA2421380A1/fr not_active Abandoned
- 2001-09-07 JP JP2002525731A patent/JP2004536020A/ja not_active Withdrawn
- 2001-09-07 EP EP01968603A patent/EP1322755B1/fr not_active Expired - Lifetime
- 2001-09-07 CA CA002421271A patent/CA2421271A1/fr not_active Abandoned
- 2001-09-07 WO PCT/US2001/028124 patent/WO2002020822A2/fr not_active Application Discontinuation
- 2001-09-07 PT PT01968603T patent/PT1322755E/pt unknown
- 2001-09-07 JP JP2002525730A patent/JP2004533803A/ja not_active Withdrawn
- 2001-09-07 WO PCT/US2001/028045 patent/WO2002020724A2/fr not_active Application Discontinuation
- 2001-09-07 CA CA002421200A patent/CA2421200A1/fr not_active Abandoned
- 2001-09-07 EP EP01970681A patent/EP1315830A4/fr not_active Withdrawn
- 2001-09-07 CA CA002421191A patent/CA2421191A1/fr not_active Abandoned
- 2001-09-07 AT AT01968603T patent/ATE478141T1/de not_active IP Right Cessation
-
2010
- 2010-12-13 JP JP2010277247A patent/JP2011120587A/ja not_active Withdrawn
-
2011
- 2011-11-09 JP JP2011245272A patent/JP5591209B2/ja not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999046284A2 (fr) * | 1998-03-13 | 1999-09-16 | The Burnham Institute | Molecules se logeant dans divers organes ou tissus |
Non-Patent Citations (4)
Title |
---|
ARAP W ET AL: "CANCER TREATMENT BY TARGETED DRUG DELIVERY TO TUMOR VASCULATURE IN A MOUSE MODEL", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 279, 16 January 1998 (1998-01-16), pages 377 - 380, XP000857470, ISSN: 0036-8075 * |
ELLERBY H M ET AL: "ANTI-CANCER ACTIVITY OF TARGETED PRO-APOPTOTIC PEPTIDES", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 5, no. 9, September 1999 (1999-09-01), pages 1032 - 1038, XP000995556, ISSN: 1078-8956 * |
RAJOTTE D ET AL: "MEMBRANE DIPEPTIDASE IS THE RECEPTOR FOR A LUNG-TARGETING PEPTIDE IDENTIFIED BY IN VIVO PHAGE DISPLAY", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 17, 23 April 1999 (1999-04-23), pages 11593 - 11598, XP000869582, ISSN: 0021-9258 * |
WANG H ET AL: "Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 18 JAN 2000, vol. 97, no. 2, 18 January 2000 (2000-01-18), pages 847 - 852, XP001206541, ISSN: 0027-8424 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1315512A4 (fr) | Ciblage ad noviral et manipulation de la r ponse du syst me immunitaire au moyen de peptides ciblants | |
WO2001051604A3 (fr) | Procedes d'identification de cibles de medicaments anticancereux | |
AU5464000A (en) | Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins | |
AP2004002986A0 (en) | Use of biologically active HIV-1 TAT, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases | |
AU5161800A (en) | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases | |
DE69922933D1 (de) | Anwendungen für humane nicht autologe, mesenchymale stammzellen | |
CY1107351T1 (el) | Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης | |
AU688101B2 (en) | Live vaccine for the treatment of tumour diseases | |
ATE287958T1 (de) | Verbesserte krebstherapie | |
EP1070122A4 (fr) | Induction de l'expression de genes apoptotiques ou cytotoxiques par co-apport de genes a mediation adenovirale | |
ES2439954T3 (es) | Vectores víricos recombinantes para la prevención y la protección contra la infección por alfavirus | |
DE60129069D1 (de) | Hepatitis B Virus Vektoren für Gentherapie | |
Sangro et al. | Gene therapy of hepatocellular carcinoma and gastrointestinal tumors | |
ATE239749T1 (de) | Phosphor-enthaltende dendrimere als transfektionsagente | |
EP1593742A3 (fr) | Vecteurs adénoviraux recombinants pour l'infection spécifique de céllules qui expriment des proteines fibreuses chimériques | |
De Giovanni et al. | The prospects for cancer gene therapy | |
EP1494705B1 (fr) | Composition et procede destines a tuer des tumeurs | |
ATE210990T1 (de) | Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt | |
Sikora et al. | Genetic drug activation strategies for breast cancer | |
MX9708615A (es) | Terapia de genes animales. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030307 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PASQUALINI, RENATA Inventor name: ARAP, WADIH |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050923 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20051217 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PASQUALINI, RENATA Inventor name: ARAP, WADIH |